ArticlePloS one2026
Early tumour size changes from neoadjuvant chemotherapy as a predictor of pathologic response in breast cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemotherapy (NAC) is the standard of care for locally advanced, human epidermal growth factor receptor 2-positive, and triple negative breast cancer. While complete pathologic response is associated with improved outcomes, NAC response varies and is only assessed post-surgery. Identifying response earlier can allow for timely treatment personalization, reducing toxicity and costs as well as improving efficacy. This study aimed to assess the feasibility of using early changes in tumour size, as measured by ultrasound during chemotherapy at 6 times, to predict final pathological response to NAC in breast cancer patients. Eligible participants were ≥18 years with biopsy-proven stage l-lll breast cancer who received standard NAC and underwent ultrasound imaging at weeks 0, 1, 4, 8, 12, and 16 during chemotherapy. A modified response grading system based on post-operative histopathological evaluation was used to classify patients as Complete Responders (CR), Partial Responders (PR), Weak Responders (WR), or Non-Responders (NR). Changes in tumour diameter, area, and volume were evaluated as early predictors of final pathologic response. Statistical analysis was performed to assess changes from baseline to each time point across pairs of groups. A total of 106 patients were included. Post-NAC response rates were assessed for each group. CRs displayed steep reductions in diameter, area, and volume in the early weeks of NAC, while PRs showed more consistent and moderate decreases. WRs demonstrated less pronounced reductions, and NRs remained largely unchanged across all time points. Statistical analysis confirmed differences in tumour size changes between CRs and other groups (p < 0.05), supporting the observed trends in diameter, area, and volume reductions. Overall, early changes in tumour size may provide some predictive value for final pathologic response to NAC but are likely insufficient on their own, underscoring the need for more robust predictive markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.